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Abstract
Staphylococcus aureus causes a spectrum of human infection. Diagnostic delays and uncertainty lead to treatment delays
and inappropriate antibiotic use. A growing literature suggests the host’s inflammatory response to the pathogen
represents a potential tool to improve upon current diagnostics. The hypothesis of this study is that the host responds
differently to S. aureus than to E. coli infection in a quantifiable way, providing a new diagnostic avenue. This study uses
Bayesian sparse factor modeling and penalized binary regression to define peripheral blood gene-expression classifiers of
murine and human S. aureus infection. The murine-derived classifier distinguished S. aureus infection from healthy controls
and Escherichia coli-infected mice across a range of conditions (mouse and bacterial strain, time post infection) and was
validated in outbred mice (AUC.0.97). A S. aureus classifier derived from a cohort of 94 human subjects distinguished S.
aureus blood stream infection (BSI) from healthy subjects (AUC 0.99) and E. coli BSI (AUC 0.84). Murine and human responses
to S. aureus infection share common biological pathways, allowing the murine model to classify S. aureus BSI in humans
(AUC 0.84). Both murine and human S. aureus classifiers were validated in an independent human cohort (AUC 0.95 and
0.92, respectively). The approach described here lends insight into the conserved and disparate pathways utilized by mice
and humans in response to these infections. Furthermore, this study advances our understanding of S. aureus infection; the
host response to it; and identifies new diagnostic and therapeutic avenues.
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Introduction
Septicemia causes substantial morbidity and mortality among
patients in the United States, with a rising burden of Staphylococcus
aureus infection [1,2]. Although blood cultures are the diagnostic
gold standard for blood stream infection (BSI), sensitivity is limited
and results are not rapidly available [3]. Such diagnostic delays
can extend the time to administration of effective antibiotics,
which is an independent risk factor for mortality [4,5]. Conversely,
diagnostic uncertainty also leads to high rates of empiric
overtreatment, fueling the burden of antimicrobial resistance
[6,7]. Thus, novel approaches that are faster and more accurate
are needed to differentiate between the major pathogens causing
sepsis and BSI.
Whereas conventional diagnostic approaches have focused on
identifying the infecting pathogen, a growing body of evidence
suggests that the host’s inflammatory response to the pathogen also
represents a potential diagnostic tool. In vitro and in vivo
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experiments have revealed fundamental differences in host
response to Gram-positive and Gram-negative bacterial infection
[8–10], including significant differences in Toll-like receptor
(TLR) signaling [11,12] and cytokine production [13,14].
Distinctive gene expression profiles exist for viral [15,16], bacterial
[17,18], and fungal infections [19,20] in both animal model
systems and ex vivo stimulation of human peripheral blood
leukocytes. Peripheral blood mononuclear cell (PBMC) gene
expression signatures have also been evaluated in humans for a
variety of conditions including severe infection [21], bacterial vs.
viral illness [10], systemic lupus erythematosus [22], atherosclero-
sis [23], and radiation exposure [24]. Taken together, these studies
provide strong evidence that global changes in host blood gene
expression patterns can be used to differentiate disease states.
The current study used S. aureus and Escherichia coli as
prototypical Gram-positive and Gram-negative bacteria due to
their prevalence and clinical relevance. Host gene expression was
measured in mice with bacterial infection across multiple
conditions. From these data, we derived a molecular classifier
for S. aureus infection in inbred mice and validated it in a cohort of
outbred mice. Next, we used host gene expression data from a
well-characterized cohort of septic human subjects to identify a
molecular classifier that accurately distinguished S. aureus BSI from
E. coli BSI or uninfected controls. Murine and human S. aureus
classifiers exhibited significant similarity particularly in comparing
S. aureus infection to the healthy state. Furthermore, both murine
and human classifiers were validated in an independent human
cohort. This study is the first to demonstrate that the in vivo host
response to Gram-positive infections is conserved from mouse to
human and can be harnessed as a novel diagnostic strategy in
patients with bacterial sepsis.
Materials and Methods
Ethics Statement
All animal experiments were carried out in strict accordance
with the recommendations of NIH guidelines, the Animal Welfare
Act, and US federal law. All animal procedures were approved by
the Institutional Animal Care and Use Committee (IACUC) of
Duke University (IACUC number: #1310905) which has been
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) International. All animals
were housed in a centralized and AAALAC accredited research
animal facility that is fully staffed with trained husbandry,
technical, and veterinary personnel. The Institutional Review
Boards at Duke University Medical Center, the Durham VA
Medical Center, and Henry Ford Hospital approved the human
studies referenced in this work. Written informed consent was
obtained for all subjects after the nature and possible consequences
of the studies were explained.
Preparation of Bacterial Cells
One methicillin-susceptible S. aureus (Sanger 476) and three
methicillin-resistant S. aureus genetic backgrounds (USA100,
USA300, and MW2) were used. Overnight S. aureus cultures were
inoculated into fresh tryptic soy broth and incubated aerobically at
30uC to log-phase growth (optical density 600 nm of ,1.0) [25].
Cells were harvested by centrifugation, rinsed, and resuspended in
phosphate-buffered saline (PBS). E. coli O18:K1:H7 was grown at
30uC overnight in Luria-Bertani broth [26]. Cultures were then
diluted with fresh medium and grown for an additional 1 to 2
hours. Upon reaching log phase, cells were treated as described for
S. aureus.
Human Subjects
Subjects were enrolled at Duke University Medical Center
(DUMC; Durham, NC), Durham VAMC (Durham, NC), UNC
Hospitals (Chapel Hill, NC), and Henry Ford Hospital (Detroit,
Michigan) as part of a prospective, NIH-sponsored study to
develop novel diagnostic tests for severe sepsis and community-
acquired pneumonia (ClinicalTrials.gov NCT00258869) [27,28].
Enrolled patients had a known or suspected infection and
exhibited two or more Systemic Inflammatory Response Syn-
drome criteria [29]. Patients were excluded if they had an
imminently terminal co-morbid condition, advanced AIDS (CD4
count ,50), were being appropriately treated with an antibiotic
pre-enrollment, or were enrolled in another clinical trial. Blood
was drawn for microarray analysis on the day of hospital
presentation with the exception of two subjects (S19 and S29).
In these latter two cases, blood was not available for microarray
preparation from that time point. However, blood drawn 24 hours
into the hospitalization was available and so was used. Subjects in
the current report had culture-confirmed monomicrobial BSI due
to S. aureus (n = 32; median age 58 years; range 24–91) or E. coli
(n = 19; median age 58; range 25–91). Uninfected controls (n = 43;
median age 30 years; range 23–59) were enrolled at DUMC as
part of a study on the effect of aspirin on platelet function among
healthy volunteers [30]. Subjects were recruited through adver-
tisements posted on the Duke campus. Blood used to derive gene
expression data in these healthy controls was drawn prior to
aspirin challenge.
Murine Sepsis Experiments
Except where noted, mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and allowed to acclimate for 7 days.
All experiments were performed on 6–8 week old mice. For the
murine S. aureus classifier, seven inbred mouse strains (3 mice/
strain: 129S1/SvImJ, A/J, AKR/J, BALB/cByJ, C57BL/6J,
C3H/HeJ, and NOD/LtJ) were IP inoculated with 107 CFU/g
of S. aureus Sanger476, euthanized at 2h after injection, and bled.
This was repeated using the four different S. aureus genetic
backgrounds (USA100, USA300, MW2, and Sanger476) in A/J
mice (n = 3 per S. aureus background). For time series experiments,
both A/J and C57BL/6J mouse strains were IP inoculated with S.
aureus Sanger476 as above, and sacrificed at 2, 4, 6, and 12 h after
injection (n = 5 per mouse strain at each time point). For survival
experiments, mice were monitored twice daily after injection and
culled upon reaching a moribund state. Animal sacrifice was
carried out by carbon dioxide inhalation. Blood was collected by
intracardiac puncture and stored in RNAlater at 270uC for
microarray experiments.
The murine E. coli infection model was carried out as described
above except a smaller inoculum (66104 CFU/g) was used.
Furthermore, the time at which animals were sickest but still alive
was 24 hours for E. coli inoculation, which is later than for S. aureus.
Consequently, A/J and C57BL/6J mice inoculated with E. coli
were sacrificed 24 h after challenge (n = 5 per mouse strain).
Control mice were not injected.
Outbred CD-1 mice were purchased from Charles River
Laboratories (Wilmington, MA) to validate the murine S. aureus
classifier. CD-1 mice were IP inoculated with 107 CFU/g of S.
aureus (USA300 and Sanger 476) and 66104 CFU/g of E. coli.
Animals including controls were sacrificed at 2 and 24 h post-
infection (n = 10 mice per pathogen at each time point). Blood was
collected and stored as described for the derivation cohort.
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Microarray Preparation (Additional Details Available in
Methods S1)
Total RNA was extracted from mouse blood using the Mouse
RiboPure Blood RNA kit (Ambion, Austin, TX) according to the
manufacturer’s instructions. Globin mRNA was removed from
whole blood RNA using the Globinclear kit (Ambion, Austin, TX).
All samples passed the quality criteria of the Agilent Bioanalyzer
and were used for microarray analysis. Since the total RNA yield
of many samples was low, one round of linear amplification was
performed for all samples using the MessageAmp Premier kit
(Ambion, Austin, TX). RNA integrity numbers were calculated for
all samples and found to be within tolerance limits. Microarrays
were normalized using Robust Multichip Average (RMA).
Affymetrix GeneChip Mouse Genome 430 2.0 Arrays were used
(Santa Clara, CA). Biotin-labeled cDNA was hybridized to the
arrays for 16 hours at 45uC according to the manufacturer’s
instructions. Arrays were then washed and labeled with strepta-
vidinphycoerythrin (strep-PE), and the signal was amplified using
biotinylated antistreptavidin followed by another round of staining
with strep-PE. These steps were performed on the Affymetrix
fluidics station according to the recommended protocol. Ampli-
fication and microarray hybridization were performed at the Duke
University Microarray Core. Labeled gene chips were scanned
using an Affymetrix Genechip Scanner 7G (Santa Clara, CA).
This array contains 45,101 probe sets to analyze the expression
level of over 39,000 transcripts and variants from over 34,000
mouse genes.
Human microarrays were prepared by first extracting total
RNA from human blood using the PAXgene Blood RNA Kit
(Qiagen, Valencia, CA) according to the manufacturer’s recom-
mended protocol including DNase treatment. RNA quantity and
quality was assessed using the Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA). RNA integrity numbers were calculated for all
samples and found to be within tolerance limits. Microarrays were
normalized using RMA. Hybridization and microarray data
collection was then performed at Expression Analysis (Durham,
NC) using the GeneChip Human Genome U133A 2.0 Array
(Affymetrix, Santa Clara, CA) according to the ‘‘Affymetrix
Technical Manual’’. Fluorescent images were detected in a
GeneChip Scanner 3000 and expression data was extracted using
the GeneChip Operating System v 1.1 (Affymetrix). All Gene-
Chips were scaled to a median intensity setting of 500. Murine and
human microarray data have been deposited in the NCBI GEO
(accession # GSE33341).
Deriving the Murine and Human S. aureus Classifiers
Microarray data was analyzed in two steps following the analysis
strategy previously outlined and utilized [19]. First, a Bayesian
sparse factor model was fit to the expression data without regard to
phenotype [31,32]. Second, factors were then used as independent
variables to build a penalized binary regression with variable
selection model [33] trained to identify S. aureus infection. In order
to minimize issues with overfitting, batch was not included in the
regression models. We used a Bayesian penalized regression
technique for variable selection which allows for weighted model
averaging of the resultant models, such that weights are computed
from model fit on the training data [33]. The model averaging
approach incorporates uncertainty in choice of model as well as
regression coefficient. This has been shown to lead to out of
sample predictive accuracies that are superior to penalized
maximum likelihood approaches [34]. Assumptions for this
approach are typical of probit regression including a linear
response surface between predictors and the transformed latent
probability variable. Genes were filtered for analysis using non-
specific filtering for genes with high mean expression and high
variance across samples. Samples with a high number of outlying
genes were removed during the factor analysis. Mice were batched
into discrete experiments with each experiment containing the
relevant controls to avoid confounding. The development and
application of this methodological approach has been previously
described [15,19,31,32,35–42]. Using the same murine experi-
mental data, another classifier was derived to classify methicillin-
resistant vs. methicillin-sensitive S. aureus infection. The method-
ology was otherwise the same as that described above.
We fit a factor model on the human data independently from
the mouse data. The factor model was fit to 9,109 genes after non-
specific filtering to remove unexpressed and uniformly expressed
genes. Z-scores were computed independently for each gene
without regard to experimental design. Subjects with absolute z-
scores greater than 3 in more than 5% of the genes on the array
were identified as outliers and were not used to fit the factor
model. The factor model was trained on the 91 samples (after
removal of three outliers) from three batches of expression data,
and this resulted in 79 factors. These 79 factors were then
projected onto the full data set (including the three subjects
removed for validation) with the goal of distinguishing S. aureus BSI
from healthy controls or E. coli BSI. Leave-one-out cross-validation
was utilized in order to control for overfitting of the penalized
binary regression model. In order to minimize issues with
overfitting, batch was not included in the regression models.
Matlab (Natick, MA, USA) scripts to perform these operations are
available. Nonparametric testing was used to evaluate model
performance (Wilcoxon rank sum for 2-group comparisons or
Kruskal-Wallis for 3 or more-group comparisons) unless otherwise
indicated.
One limitation of this approach is that the marginal significance
of genes within the factor-based classifier cannot be defined.
Instead, gene lists were created to identify genes with differential
expression between specified groups with respect to gene-level and
factor-level analyses. For 3-group comparisons (S. aureus vs. E. coli
vs. Healthy controls) one-way analysis of variance (ANOVA) was
used. For pairwise comparisons, Student’s t-test was used. Results
were statistically significant at p,0.05 after Bonferroni correction
for multiple testing. Spreadsheets of gene/factor lists are provided
as supplemental material.
Creating a Human Ortholog of the Murine S. aureus
Classifier
We used Chip Comparer (http://chipcomparer.genome.duke.
edu/) to identify human orthologs for all possible mouse genes.
When there were multiple orthologs, we preferentially used the
anti-sense target probes that shared the fewest probes with other
genes as identified by the probe label. Chip Comparer identified
17,600 probe sets on the Affymetrix GeneChip Human Genome
U133A 2.0 Array that have orthologs in the Affymetrix GeneChip
Mouse Genome 430 2.0 Array. Factor scores from the mouse
factor model were estimated using this set of 17,600 genes as
follows: Given a matrix of expression values, X, and a factor model
X = BF+e, we first replaced missing values by mean expression
levels for those genes. Step 2: Inverse regression was utilized to
compute F*, to estimate the factor scores. Step 3: We estimated X
by computing BF* and replaced missing values with the
corresponding values from this matrix. Steps 2 and 3 were then
repeated until the estimates for the missing values converged.
External Validation in an Independent Cohort
To externally validate the murine and human S. aureus
classifiers, we utilized publically available expression data from a
Gene Expression Classifier for S. aureus Infection
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pediatric cohort with S. aureus infection and healthy controls [18].
Hospitalized children with invasive S. aureus infection were
enrolled with sample collection occurring after microbiological
confirmation. Healthy controls included children undergoing
elective surgical procedures and at healthy outpatient clinic visits.
This dataset includes multiple expression platforms. For the
purposes of consistency, we only included subjects with Affymetrix
U133A data yielding 46 S. aureus-infected patients and 10 healthy
controls. Given the absence of subjects with E. coli infection in the
validation cohort, we derived new murine and human S. aureus
classifiers that excluded animals or subjects with E. coli infection.
These classifiers were derived and then projected onto the 56-
sample validation cohort as described heretofore.
Heat Map Generation
In order to generate heat maps of gene expression, we first
turned to the factors from the murine and human S. aureus
classifiers. Probes from each factor were identified and tested for
differential expression in a one-way ANOVA. Probes with
significantly different levels of expression after Bonferroni correc-
tion were retained. For the murine data, there were thousands of
probes (,1000–3000, typically) meeting these criteria. Conse-
quently, the p-values were sorted in ascending order and the 100
most significant probes from each factor were retained. Duplicate
probes across the factors were removed. The human expression
heat map was created in the same manner except all significant
probes are presented considering there were fewer factors and
genes in the human S. aureus classifier as compared to the murine
classifier. Heat maps were generated using Matlab (Natick, MA,
USA).
Pathway Analysis
Pathway analysis for functional annotation of genes was
performed with the MetaCore tool of the GeneGO package
(GeneGo, Inc., St. Joseph, MI, USA) (http://www.genego.com).
P-values were assigned to pathways based on the number of genes
mapping to a particular pathway relative to the total number of
genes in that pathway. Statistically significant pathways were
defined as a p-value ,0.05 (False Discovery Rate [FDR]-adjusted)
based on hypergeometric distributions [19].
Results
Murine Sepsis due to S. aureus and E. coli
Clinically relevant S. aureus infections in humans typically arise
from a primary focus with secondary dissemination. To mimic this
process, mice were inoculated via the intraperitoneal (IP) route
[25]. Infection-susceptible and infection-resistant inbred mouse
strains (A/J and C57BL/6J, respectively) [43,44] were inoculated
with S. aureus (Sanger476) or E. coli (O18:K1:H7) (n = 5 per mouse
strain and bacterial species). A survival analysis was carried out to
determine the optimal duration of infection for subsequent
experiments (Figure S1A). Based on this data, A/J and
C57BL/6J mice were infected with S. aureus (sacrificed at t = 0,
2, 4, 6, and 12 hours post-infection; n = 10 animals/time point) or
E. coli (t = 0, 2, 6, 12, and 24 hours post-infection; n = 10 animals/
time point). The effect of infection status, bacterial pathogen, and
duration of infection on global patterns of gene expression was
assessed using principal component analysis (PCA) (Partek
Genomics Suite) (Figure S1B-D) [45]. Gene expression patterns
clustered by infection status and by pathogen (S. aureus vs. E. coli).
Animals infected with S. aureus demonstrated a time-dependent
change in gene expression that first manifested at two hours, by
which time bacteremia has occurred [46]. This pattern remained
stable through 12 hours, when most animals have succumbed to
sepsis. E. coli-infected animals did not reveal this time-dependent
progression based on the time points sampled, but had a distinctly
different pattern of gene expression that was evident at 2 hours
and persisted through 24 hours following infection. A heat map
depicting the time-dependent nature of these gene expression
changes is presented in Figure S2.
Peripheral Blood Gene Expression Signatures Classify S.
aureus-infected from Uninfected Mice
To create a host gene expression-based classifier for S. aureus
infection, mice from a variety of experimental conditions were
utilized (n = 187 total). Seven strains of inbred mice were
challenged with 4 S. aureus genetic backgrounds via IP inoculation
and sacrificed at various time points as described in Experimental
Procedures. The comparator group for model derivation included
50 A/J or C57BL/6J mice inoculated with E. coli (O18:K1:H7) as
well as 54 non-inoculated mice. Whole blood mRNA was used to
generate microarray expression data. A list of differentially
expressed genes is presented in Table S1. Figure S3 presents
the number of overlapping genes in each pairwise comparison.
Patterns of co-expressing genes were defined using sparse latent
factor regression in an unsupervised manner (i.e. without
knowledge of the source animal’s infection status) [31,32]. Factor
models are a well-known technique for describing correlation
structure in high dimension, low sample size data sets. Our sparse
latent factor model works by collecting genes that are highly
correlated into groups. Predictive models are then built from the
latent factors – vectors that describe the aggregate behavior of the
group. Subsequently, these factors served as independent variables
in a variable selection, binary regression model to distinguish
animals with and without S. aureus infection. This approach was
taken in lieu of using individual gene expression changes for
several reasons. A given gene with biological relevance may be
differentially expressed in response to S. aureus infection but not to
the degree that would meet statistical significance. Considering this
altered gene expression exists amid a network of other such
changes, the collective perturbations in that particular pathway
would be more easily detected using factor analysis. Furthermore,
changes across multiple biological pathways will be reflected across
multiple factors. These can then be collectively harnessed for their
diagnostic potential using a binary regression model.
Thirty factors were identified, of which 16 demonstrated a
pattern of expression significantly associated with infection status
(mFactors 15, 7, 23, 13, 9, 29, 28, 2, 17, 16, 21, 1, 5, 4, 26, and 19
in order of greatest significance; ANOVA; p,0.0017 for S. aureus
vs. control vs. E. coli after Bonferroni correction; Figure S4).
These 30 factors were fitted into a penalized binary regression
model, termed the ‘‘murine S. aureus classifier’’. The best
performing model, as defined by the model with the largest log-
likelihood value, included four factors (mFactors 7, 15, 23, and 26).
Other models may be just as adequate, but we are only referring to
this ‘‘top’’ model. Leave-one-out cross-validation was used to
control overfitting and to estimate the model’s performance in
subgroups of experimental conditions as described below (mouse
strain, S. aureus genetic background, duration of infection, and
bacterial species [S. aureus vs. E. coli]). A schematic of the derivation
and validation experiments is depicted in Figure 1.
The ability of the murine-derived host gene expression classifier
to identify S. aureus infection was tested in 7 inbred mouse strains of
varying infection susceptibilities [43]. In all 7 strains, the murine S.
aureus classifier accurately differentiated S. aureus-infected from
control mice (p = 4.89610216; AUC = 0.9964) (Figure 2A). The
ability to characterize S. aureus infection persisted when A/J mice
Gene Expression Classifier for S. aureus Infection
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(infection-susceptible) were challenged with four different S. aureus
backgrounds: USA100 (the predominant US nosocomial methi-
cillin resistant S. aureus [MRSA] genetic background); USA300 (the
predominant US community-acquired MRSA genetic back-
ground); USA400 (MW2); and Sanger 476 (a methicillin-
susceptible genetic background) (p = 1.92610210 vs. control mice;
AUC = 1.00) (Figure 2B). Furthermore, the murine S. aureus
classifier consistently discriminated S. aureus infected mice from
controls at 2, 4, 6, and 12 hours post-inoculation (p = 4.41610216
vs. uninfected mice; AUC 1.00) (Figure 2C). This time interval
was selected because two hours is the earliest time point at which
S. aureus can be cultured from blood; while 12 hours was the point
at which animals began to die of S. aureus sepsis (Figure S1A). In
summary, a classifier based on murine-derived host gene
expression accurately identified the presence of S. aureus infection
in mice under a variety of host, pathogen, and temporal
conditions.
Murine S. aureus Classifier Distinguishes S. aureus-
infected from E. coli-infected Mice
Next, we determined whether the murine S. aureus classifier
could differentiate S. aureus from E. coli infection. Both the
infection-susceptible A/J and infection-resistant C57BL/6J strains
were infected with either S. aureus (Sanger 476) or E. coli
(O18:K1:H7). Animals were sacrificed at 2, 6, and 12 hours after
inoculation. The murine S. aureus classifier correctly identified 50
of 53 (94.3%) animals as either infected with S. aureus or not at 2
hours (50/53), 100% of animals at 6 hours (n = 20), and 96.7% of
animals at 12 hours (29/30) (Figure 3A). This corresponded to an
overall p-value of 7.94610226 by Kruskal-Wallis test (comparing
S. aureus vs. E. coli vs. Healthy controls) with an AUC of 0.9935
across all time points. Next, the murine S. aureus classifier was
independently validated in outbred CD-1 mice with S. aureus
infection (Sanger 476 or USA300), E. coli infection (O18:K1:H7),
or uninfected controls (10 animals per condition). The murine-
derived S. aureus model accurately classified 95% of all animals
where the reference standard was the known experimental
condition (38/40; p = 1.4761026; 90% sensitivity and 100%
specificity; AUC = 0.9775) (Figure 3B).
The murine S. aureus classifier was generated to identify S. aureus
infection within a population including both healthy and E. coli-
infected animals. However, it is possible this classifier is primarily
distinguishing ‘‘sick’’ from ‘‘not-sick’’ phenotypes. In such a case, it
would be expected that the classifier would still differentiate
animals with E. coli infection from uninfected controls. However,
this was not observed (AUC 0.5089; p = 0.8785) demonstrating the
Figure 1. Schematic of derivation and validation cohorts. The Murine Derivation Cohort includes S. aureus infection (n = 83), healthy control
mice (n = 54), and E. coli infection (n = 50). It served as a validation cohort to assess Mouse Strain Effect, S. aureus Genetic Background Effect, Time
Course, and to compare S. aureus vs. E. coli and E. coli vs. Healthy. The murine S. aureus classifier was externally validated in Outbred Mice (n = 30) and
the CAPSOD Human Cohort. The CAPSOD Human Cohort includes S. aureus BSI (n = 32), healthy volunteers (n = 43), and E. coli BSI (n = 19). It served as
a validation cohort to compare S. aureus vs. Healthy, S. aureus vs. E. coli, and E. coli vs. Healthy. Model derivation and validation using the entire cohort
of animals or humans is depicted by the blue outline and arrows. An independent classifier was generated using only subjects with S. aureus or E. coli
BSI (green outline). This classifier was validated using leave one out cross validation (green arrow). The Human Pediatric Cohort (n = 46 S. aureus, 10
Healthy) used for external validation does not include patients with E. coli infection. Therefore, S. aureus classifiers were generated from the murine
and CAPSOD cohorts that excluded E. coli data (red outline and thick red arrow). The Human Pediatric Cohort was used to derive a Human S. aureus
vs. Healthy classifier which was validated in the S. aureus-infected and Healthy populations within the murine and CAPSOD human cohorts (thin red
arrow).
doi:10.1371/journal.pone.0048979.g001
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specificity of this classifier for S. aureus infection. Thus, a murine-
derived host gene expression classifier accurately distinguished S.
aureus-infected from E. coli-infected or uninfected mice across
multiple host strains, pathogens, post-infection time points, and
was validated in outbred mice.
Given this ability to discriminate infection due to different
bacterial species, we further explored the potential for a factor-
based classifier to distinguish infection due to methicillin-resistant
(MRSA) or methicillin-sensitive S. aureus (MSSA), which have been
shown to differ in their pathogenicity and virulence. The same 30
factors described above were fitted into a penalized binary
regression model with the specific aim of differentiating MRSA
from MSSA infection. Leave-one-out cross-validation was used to
control overfitting and to estimate the model’s performance in a
population of 19 MRSA-infected and 84 MSSA-infected mice
(Figure S5). Despite some overlap, this classifier accurately
differentiated infection due to MRSA or MSSA (AUC 0.8396;
p = 4.1461026). Genes discriminating infection due to MRSA or
MSSA that remained significant after adjusting for multiple tests
are presented in Table S2.
Human S. aureus Classifier
We next determined whether peripheral blood gene expression
in humans could yield a classifier for S. aureus BSI. Peripheral
whole blood mRNA from 32 patients with S. aureus BSI, 19
patients with E. coli BSI, and 43 healthy control subjects were used
Figure 2. Murine S. aureus classifier accurately identifies S. aureus infection under a variety of conditions. Conditions represented
include different murine hosts (A), bacterial genetic backgrounds (B), and time from inoculation (C). Animals with S. aureus infection are depicted by a
red ‘‘x’’. Uninfected control mice are depicted by black circles.
doi:10.1371/journal.pone.0048979.g002
Figure 3. The murine S. aureus classifier differentiates S. aureus from E. coli infection. (A) Inbred mice were tested under three conditions:
uninfected controls (black circles), S. aureus infected (red ‘‘x’’), and E. coli infected (blue triangles). The y-axis represents the predicted probability that
a given animal was infected with S. aureus. (B) The murine S. aureus classifier is validated in outbred CD-1 mice where it differentiates S. aureus
infection from E. coli infection and uninfected controls.
doi:10.1371/journal.pone.0048979.g003
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to generate microarray data (Table 1). A list of differentially
expressed genes is presented in Table S3. Figure S6 presents the
number of overlapping genes in each pairwise comparison.
Seventy-nine factors were defined and fitted into a linear
regression model trained to identify the presence of S. aureus
BSI. Although 17 factors were independently associated with S.
aureus BSI (Figure S7), only two factors remained in the best-
performing model (hFactors 20 and 74). Similar to the murine S.
aureus classifier, the human S. aureus classifier was generated blind
to microbiological diagnosis in an unsupervised manner. Gender
was controlled for in the model’s derivation considering the
predilection for female sex in E. coli BSI (Table 2). We then
estimated the model’s performance in phenotypic subgroups using
leave-one-out cross-validation. The classifier accurately differenti-
ated those with S. aureus BSI from healthy controls (72/75 correctly
classified; AUC = 0.9898; p = 5.41610213) (Figure 4A). The
human S. aureus classifier also correctly distinguished S. aureus
from E. coli BSI in 82% (42/51) of cases (AUC = 0.8372;
p = 6.7761024). When the human S. aureus classifier was applied
to subjects with E. coli BSI vs. healthy controls, we observed an
intermediate level of discrimination (56/62 correctly classified;
AUC 0.9229; p = 1.3861027). This suggests that the human
classifier is partially pathogen specific since E. coli BSI could also
be distinguished from healthy controls but not with the same
degree of accuracy as S. aureus BSI. A heat map depicting these
gene expression changes is presented in Figure S8.
In the human S. aureus classifier described above, it is the
inclusion of healthy controls that drives the discrimination from S.
aureus BSI. Considering the clinical importance of differentiating
Gram-positive from Gram-negative infections, rather than sick vs.
healthy, we created a penalized binary regression model with the
specific aim of differentiating human S. aureus (n = 32) from E. coli
(n = 19) BSI. In this cohort, 52 factors were identified (different
from the 79 factors identified when Healthy was included) of
which only hFactor 40 remained in the top performing model after
controlling for gender. Using leave-one-out cross-validation
(Figure 4B), this model had a sensitivity of 62.5% (20/32 S.
aureus BSIs correctly classified) but a specificity of 94.7% (18/19 E.
coli BSIs correctly classified). This corresponds to an AUC of
0.8503 (p = 3.4761025).
A Murine S. aureus Classifier Identifies S. aureus Infection
in Humans
We then determined whether the murine S. aureus classifier
could identify S. aureus BSI in humans. To accomplish this, the
murine S. aureus classifier was projected onto human gene
expression data. Specifically, Chip Comparer (http://
chipcomparer.genome.duke.edu/) provided a modified represen-
tation of the Affymetrix Mouse Genome 430 2.0 Array that only
included orthologs of transcripts represented on the Affymetrix
Human Genome U133A 2.0 Array. This resulted in a murine S.
aureus classifier consisting only of genes with human orthologs
(68.6% of the total array representation). We then evaluated this
classifier in our human cohort. To account for potential species-
specific variation in gene expression, predicted probabilities were
plotted on a logit rather than a probabilistic scale. Using this
murine S. aureus classifier, human patients with S. aureus BSI were
distinguished from healthy controls (AUC = 0.9484;
p = 4.00610211) (Figure 5). Thus, the host response to S. aureus
infection was sufficiently conserved that a predictive model
generated in one species (Mus musculus) identified S. aureus BSI in
another (Homo sapiens). However, the murine-derived S. aureus
classifier did not differentiate between S. aureus and E. coli BSI in
humans (AUC = 0.5905; p = 0.2883).
Validation of Murine and Human Classifiers in an
Independent Pediatric Population
We externally validated the murine and human S. aureus
classifiers in an independent human cohort [18]. This validation
cohort consisted of pediatric patients hospitalized due to invasive
S. aureus infection (n = 46) and healthy controls (n = 10) who had
gene expression data generated on a compatible platform (U133A
array) with that used in this study. This cohort did not enroll
children with E. coli infections. For this reason, we excluded E. coli
infection from both classifiers. New murine and human S. aureus
classifiers were developed in the same manner described above but
without E. coli-related expression data. This modified murine S.
aureus classifier was comprised of mFactors 7, 15, and 26 but not
mFactor23. The modified human S. aureus classifier only contained
hFactor4. Both the murine and human S. aureus classifiers
differentiated children with S. aureus infection from healthy
controls in this validation cohort (murine classifier
AUC = 0.9522, p-value = 9.0361026 [Figure 6A]; human classi-
Figure 4. Performance of the human S. aureus classifier. (A) The
human S. aureus classifier differentiates S. aureus BSI from both
uninfected controls and E. coli BSI. (B) A separate classifier was
generated using only S. aureus and E. coli-infected human subjects and
tested using leave-one-out cross-validation.
doi:10.1371/journal.pone.0048979.g004
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Table 1. Description of human subjects used to generate a S. aureus classifier.
Subject Subject Category Race Age Gender Source of Infection Positive Culture Sources WBC PMN %
S1 S. aureus White 82 Male Endocarditis Blood 23.6 96.4
S2 S. aureus White 70 Female Skin Blood, Wound, Operative cultures 11.6 N/Aa
S3 S. aureus Black 41 Male Catheterb Blood 14.8 N/A
S4 S. aureus White 81 Male Skin Blood, Pleural fluid 16.2 N/A
S5 S. aureus White 81 Male Bone Blood 17.3 N/A
S6 S. aureus Black 55 Male Catheter Blood, Vascular catheter site 14.3 89.8
S7 S. aureus Black 69 Female Catheter Blood 13 N/A
S8 S. aureus Black 44 Female Catheter Blood 13 90
S9 S. aureus Black 51 Male Skin Blood 6.9 73
S10 S. aureus Black 47 Male Skin Blood 12 87
S11 S. aureus White 36 Female Endocarditis Blood 22.7 85
S12 S. aureus White 54 Male Bone Blood 9.8 88
S13 S. aureus Black 55 Male Bone Blood, Skin, Synovial fluid 18.3 87
S14 S. aureus Black 42 Male Unknown Blood, Urine, Sputum 7.6 82
S15 S. aureus Black 52 Male Bone Blood 10.9 79
S16 S. aureus Black 55 Male Bone Blood, Skin 28.6 95
S17 S. aureus White 52 Male Skin Blood, Skin 17.9 84
S18 S. aureus N/A 51 Female Lung Blood 19.8 78
S19 c S. aureus Black 40 Male Skin Blood, Skin 14.7 93
S20 S. aureus White 60 Male Skin Blood N/A N/A
S21 S. aureus Black 59 Male Catheter Blood 7.5 75.5
S22 S. aureus Black 58 Male Bone Blood 27.9 N/A
S23 S. aureus Black 77 Male Urinary tract Blood, Urine, Skin 9.8 80.3
S24 S. aureus Black 91 Male Bone Blood 15.1 93
S25 S. aureus White 75 Female Catheter Blood 6 92
S26 S. aureus Black 58 Male Catheter Blood 23.9 87
S27 S. aureus Black 24 Male Urinary Tract Blood, Urine, Sputum 16 76.4
S28 S. aureus White 74 Male Skin Blood, Abscess 33.2 89
S29 c S. aureus Black 70 Male Skin Blood 19.6 82
S30 S. aureus White 61 Male Bone/CNSd Blood, Abscess 10.4 86
S31 S. aureus, S. pneumoniae Black 52 Male Lung Blood (S. aureus); Antigen test (S.
pneumoniae)
6.1 93
S32 S. aureus Black 38 Male Endocarditis Blood 16.8 94
E1 E. coli Black 43 Female Urinary tract Blood, Urine 32.6 87.3
E2 E. coli White 49 Female Urinary tract Blood 14 92.4
E3 E. coli Black 44 Female Urinary tract Blood, Urine 15.7 N/A
E4 E. coli White 70 Female Urinary tract Blood, Urine 20.7 88
E5 E. coli Black 40 Male Urinary tract Blood, Urine 15 83
E6 E. coli White 91 Female Urinary tract Blood, Urine 5.6 N/A
E7 E. coli Black 25 Female Urinary tract Blood, Urine 11.1 88
E8 E. coli White 62 Male Urinary tract Blood, Urine 13.3 N/A
E9 E. coli Black 70 Male Urinary tract Blood 2.4 94
E10 E. coli Black 32 Female Urinary tract Blood, Urine 25.1 N/A
E11 E. coli White 54 Female Urinary tract Blood, Urine 10.8 90
E12 E. coli White 74 Female Urinary tract Blood, Urine 7.3 97
E13 E. coli Black 79 Female Lung Blood 16.9 77
E14 E. coli Black 41 Male Urinary tract Blood, Urine 14.3 77.6
E15 E. coli White 65 Male Urinary tract Blood, Urine 21.6 85
E16 E. coli White 63 Female Urinary tract Blood, Urine 8.5 N/A
E17 E. coli White 81 Female Urinary tract Blood, Urine 14.1 86.5
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Table 1. Cont.
Subject Subject Category Race Age Gender Source of Infection Positive Culture Sources WBC PMN %
E18 E. coli Black 69 Female Urinary tract Blood, Urine 11.1 67.6
E19 E. coli White 55 Female Urinary tract Blood, Urine 7.2 87.5
H1 Healthy Black 27 Male
H2 Healthy White 24 Female
H3 Healthy White 29 Female
H4 Healthy White 26 Male
H5 Healthy Asian 30 Male
H6 Healthy Black 24 Male
H7 Healthy White N/A Male
H8 Healthy Asian 24 Male
H9 Healthy Asian 23 Male
H10 Healthy White 50 Female
H11 Healthy White 23 Female
H12 Healthy White 24 Female
H13 Healthy White 44 Male
H14 Healthy White 24 Female
H15 Healthy White 28 Female
H16 Healthy White 26 Male
H17 Healthy Asian 30 Female
H18 Healthy Black 26 Male
H19 Healthy White 25 Male
H20 Healthy White 24 Male
H21 Healthy White 24 Male
H22 Healthy Asian 25 Female
H23 Healthy Black 24 Female
H24 Healthy White 43 Female
H25 Healthy White 26 Female
H26 Healthy Black 59 Male
H27 Healthy Black 25 Female
H28 Healthy White 24 Male
H29 Healthy White 25 Male
H30 Healthy White 26 Male
H31 Healthy White 24 Male
H32 Healthy White 26 Male
H33 Healthy N/A 25 Male
H34 Healthy White 53 Female
H35 Healthy Black 45 Female
H36 Healthy White 23 Male
H37 Healthy White 26 Female
H38 Healthy White 27 Male
H39 Healthy Asian 43 Female
H40 Healthy Black 32 Female
H41 Healthy N/A 25 Female
H42 Healthy Black 43 Female
H43 Healthy White N/A Female
aN/A – Not available.
bCatheter refers to vascular catheters.
cGene expression data for S19 and S29 was generated from blood drawn on the second hospital day. Blood drawn on the day of admission was otherwise used for all
other infected subjects.
dThis subject had vertebral osteomyelitis associated with an epidural abscess.
doi:10.1371/journal.pone.0048979.t001
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fier AUC 0.9217, p-value 3.4861025 [Figure 6B]). The converse
was also true. A S. aureus classifier trained on this independent
pediatric cohort accurately discriminated S. aureus infection from
healthy controls in our CAPSOD human cohort (70/75 correctly
classified; AUC = 0.9775, p-value = 2.03610212) and murine
cohort (123/137 correctly classified; AUC = 0.9255;
p = 4.56610217).
S. aureus Infection Induces Similar Host Gene-expression
Responses in Mouse and Human
Pairwise comparisons were performed to identify genes with
significantly different levels of expression (after Bonferroni
correction). Comparisons included S. aureus infection vs. Healthy,
E. coli infection vs. Healthy, and S. aureus vs. E. coli infection in
mice and humans (Tables S1 and S3). Genes from each pairing
were entered into the GeneGo pathway map database. The 50
most significant biological pathways arising from the pairwise
comparisons are presented in Table S4. The genes represented
within common pathways are presented in Table S5. A similar
number of pathways overlapped between the murine and human
responses to S. aureus (12 of the top 50) and E. coli (14 of the top 50)
infection. Most of the overlapping pathways in the murine and
human responses to both S. aureus and E. coli belonged to the broad
category of immune response including CD28, ICOS, and the
MEF2 pathway. Cytoskeletal remodeling (TGF and WNT) and
apoptosis were also common to both infection types in mice and
humans. Some pathways were highly significant in the S. aureus vs.
Healthy comparison but not manifest in E. coli vs. Healthy such as
NF-kB-associated pathways; the CD40 immune response path-
way; and clathrin-coated vesicle transport. As expected, these
pathways were also differentially manifest in the direct comparison
of murine S. aureus and E. coli infection. We did not identify any
statistically significant probes that distinguished human S. aureus
from E. coli BSI. One probe, corresponding to the F2RL3 gene,
nearly met this statistical cutoff (p-value 5.9461026 with a cutoff of
2.2461026). F2RL3 encodes proteinase-activated receptor 4 [47].
This molecule is a G-protein coupled receptor activated by
thrombin and trypsin but has not previously been implicated in the
sepsis or immune response. It is expressed in multiple tissues with
high levels in the lung, pancreas, thyroid, testis, and small intestine
but not peripheral blood or lymphoid tissues [47].
Discussion
Early diagnostic strategies for S. aureus BSI could improve
patient care by reducing the time required to establish the
diagnosis and provide appropriate treatment while avoiding
unnecessary anti-MRSA antibiotics. The current investigation
contributes to this goal through three key findings. First, S. aureus
infection induces conserved host gene expression responses in mice
that can differentiate from E. coli-infected or uninfected mice. This
discovery was consistent and robust across multiple inbred mouse
strains, S. aureus genetic backgrounds, time points, and was
validated in outbred mice. The validation step strengthens
generalizability and is an important improvement over previous
murine gene-expression based classifiers that were developed and
tested in only a single inbred mouse strain including the fields of
infectious diseases [19,48,49]; cancer progression [50,51]; and
aging [52,53]. Furthermore, this murine predictor was specific for
S. aureus infection and not simply a marker of illness based on the
observation that mice with E. coli sepsis could not be distinguished
Table 2. Characteristics of human subjects used for S. aureus classifier derivation.
S. aureus (n = 32) Gram-negative (n = 19) Healthy (n = 43)
Age in years, mean (range) 58 (24–91) 58 (25–91) 30 (23–59)
Gender, n (%)
Female 6 (19) 14 (74) 21 (49)
Male 26 (81) 5 (26) 22 (51)
Race, n (%)
Black 20 (63) 9 (47) 9 (21)
White 11 (34) 10 (53) 26 (60)
Asian 0 0 6 (14)
Unknown 1 (3) 0 2 (5)
Dialysis, n (%) 12 (38) 0 0
Diabetes, n (%) 13 (41) 3 (16) 0
Immunosuppression, n (%) 2 (6) 2 (11) 0
doi:10.1371/journal.pone.0048979.t002
Figure 5. Projecting the mouse S. aureus classifier onto human
subjects. The murine S. aureus classifier identifies humans with S.
aureus BSI, but does not differentiate S. aureus from E. coli BSI.
doi:10.1371/journal.pone.0048979.g005
Gene Expression Classifier for S. aureus Infection
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e48979
from healthy, uninfected animals. The murine S. aureus classifier
performed equally well at multiple time points despite progression
of illness lending additional support to the specificity of this
classifier. Second, human-derived host gene expression signatures
differentiated S. aureus BSI from E. coli BSI or uninfected controls.
In contrast to the murine-based classifier, the human-based model
was less pathogen specific but still provided a significant degree of
differentiation between S. aureus and E. coli BSI. Finally, the
responses to S. aureus infection are highly conserved at the
transcriptional and pathway level. This conserved response
allowed us to validate the murine- and human-derived S. aureus
classifiers in an independent cohort of S. aureus-infected patients.
Previous efforts to identify a discriminatory host gene expression
signature for Gram-positive versus Gram-negative infections have
yielded inconsistent results. This is likely due to the observation
that transcriptional data derived from complex phenotypes such as
infection do not produce just one predictive gene set, but rather
generate multiple gene sets associated with the phenotype in
question [54]. Some studies report a common pattern of host gene
expression [55–57], whereas others have identified different
expression profiles [8–10,58]. In the current investigation, we
utilized well-established methodologies [15,19,31,36,38–41] to
derive predictors for S. aureus infection in both mice and humans
from gene expression data. A key component of this methodology
was a dimensional reduction step generating sets of co-expressed
genes, termed ‘‘factors’’. We observed that multiple, individual
factors differentiated between various infection states although
none performed universally well. For example, mFactor15 was
associated with the lowest overall p-value during model genera-
tion. The AUC was 0.9587 for S. aureus vs. uninfected control mice
but only 0.7942 for S. aureus vs. E. coli. In contrast, mFactor23 had
an AUC of 0.9800 for S. aureus vs. E. coli but an AUC of 0.5926 for
Figure 6. Validation in an independent human cohort [18]. (A) The murine S. aureus classifier differentiates between S. aureus infection and
healthy. (B) The human S. aureus classifier differentiates between S. aureus infection and healthy.
doi:10.1371/journal.pone.0048979.g006
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S. aureus vs. uninfected control mice. In order to generate a more
robust classifier, factors were used as independent variables to
generate a binary regression model. Factor models are an excellent
technique for estimating correlation structure in very high
dimensional data sets. This comprised the second step in
generating the S. aureus predictors. It was only by including all
factors to build the classifier that we could validate the model in
the broadest set of conditions including different bacterial
pathogens. However, because factors are typically made up of
many genes, it is difficult to estimate the marginal effect of
removing single genes from predictors. As such, it can be
challenging to move from predictors based on factors to predictors
based on small gene subsets. Although redundancy among the
genes in a molecular classifier is expected and is a potential
limitation, such redundancy can also improve robustness for a
specific phenotype [54] as is likely to be the case in discriminating
S. aureus from E. coli infection in mice. Comparisons at the
individual gene level, as with pairwise comparisons, are likely to
reveal differences in relatively simple biological responses. In
contrast, dimension reduction with factor modeling as utilized in
this study incorporates differences across multiple pathways,
allowing for the detection of changes in a more complex
pathobiology. Additionally, our factor model construction does
not incorporate known biological pathways. This leads to gene
groupings that are sometimes difficult to interpret. The advantage
of the approach is the extreme dimension reduction which allows
for discovery and cross-validation on very small data sets. This is
one possible explanation for why the human S. aureus classifier
differentiated S. aureus from E. coli whereas no genes met the
threshold for differential expression after Bonferroni correction in
a pairwise comparison between these two patient populations. The
strength of this approach is offset by the possibility that smaller or
transient changes in gene expression might be missed. It should be
noted that the classifiers described in this study are not intended to
be of clinical grade, which would require a more restrictive set of
discriminating genes. Furthermore, there are likely many combi-
nations of genes and factors that would perform similarly to that
described here. This study presents findings related to the best
performing classifier using the described methodologies. Defining
the smallest, non-redundant set of genes that retains adequate
discriminating power would be a vital next step in generating a
clinically-useful diagnostic. In addition, any host response-based
diagnostic requires validation across a range of clinical states.
Immunocompromise is a particular condition in which it cannot
be assumed the host immune response follows the paradigms
identified here.
The murine model has been effectively used to gain insights into
the pathophysiology of sepsis in general and S. aureus in particular
[43,44]. Murine-derived gene expression signatures have also been
successfully translated to non-infectious human conditions such as
radiation exposure and breast cancer [24,59,60]. Here, we
describe the robust performance of a murine-derived S. aureus
classifier in both mice and humans and also offer several lines of
evidence supporting a partially conserved host response to S. aureus
infection in both host species. First, the murine-based predictor
could differentiate human S. aureus BSI from uninfected controls.
Second, the genetic pathways were highly conserved. For example,
most of the relevant murine pathways were also significantly
associated with S. aureus BSI in humans. Finally, the murine-based
predictor was highly accurate in classifying S. aureus infection in an
independent human cohort.
Despite the robust performance of the murine classifier when
applied to a human population, the ideal animal model for human
sepsis remains elusive [61–63]. For example, virtually no murine-
based sepsis studies have been replicated in patients [64,65]. Other
sepsis studies in mice and humans yield discordant results. For
example, the impact of TNF-a receptor therapy on septic mice
[66] and humans [67] yielded contradictory results. In fact, more
than 60 incongruities between murine and human immune
systems have been recognized many of which involve host-
pathogen interactions [68,69]. Our results are consistent with
these earlier observations. For example, we encountered inconsis-
tences between murine and human responses to S. aureus such that
a minority (12) of the top 50 pathways overlapped between the two
species. Moreover, the human response to S. aureus when
compared to E. coli was differentiated by only one gene, F2RL3,
which nearly reached the threshold for statistical significance. This
is in contrast to the many genes identified differentiating the
murine response to S. aureus and E. coli infection although F2RL3 is
notably absent from this list. These host species-specific differences
in sepsis, as well as infection-specific characteristics such as
anatomic site of infection (e.g. genitourinary tract for E. coli vs.
skin/soft tissue for S. aureus) limit our ability to apply knowledge
gained from animal sepsis models to humans. It is also worth
noting that batch effects and their correction may introduce bias in
the form of false positives in the gene selection output [54].
However, this effect would be equally distributed among the S.
aureus infected, E. coli infected, and healthy subjects. Finally, the
ability to distinguish bacterial sepsis from healthy is expectedly
easier than the finer distinction between two offending bacterial
pathogens. It is therefore not surprising that the murine S. aureus
predictor did not differentiate S. aureus from E. coli infection in the
human cohort. Comorbid disease such as diabetes or end-stage
renal failure, which we observed in a minority of the infected
human cohort, could be confounding the analysis and driving the
differentiation between healthy human controls and those with
infection (S. aureus or E. coli BSI). Without controlling for comorbid
disease, such a confounding effect cannot be excluded. However,
the human S. aureus classifier performed exceptionally well in
differentiating infected individuals from healthy controls even in
those patients without comorbid disease. Furthermore, the murine
classifier (derived from mice without comorbid disease) could still
differentiate infected human subjects from the healthy human
cohort. These factors make it unlikely that comorbid disease is
playing a significant role in the analysis although future attempts at
deriving a gene-expression-based classifier should make accom-
modations for the possible confounding effect of comorbid disease.
Gene expression changes in peripheral blood cells drive the
derivation of both the murine and human S. aureus classifiers. It is
conceivable these gene expression changes are reflective of
transcript abundance driven by myeloid cell lineage expansions
and are not pathogen or infection specific. However, previously
published data and work presented here suggest this is not the
case. For example, Ardura et al. found no differences in the
absolute numbers of total B and T cells in patients with S. aureus
infection compared to healthy controls [18]. Yet the abundance of
lymphocyte-specific transcripts was significantly reduced. In
contrast, expansion of the myeloid lineage was associated with
high levels of expression among genes associated with neutrophil
function. A similar independence between lymphocyte counts and
differential gene expression within this lineage was observed in an
independent pediatric sepsis cohort [70]. In another example,
transcript abundance due to cell lineage expansions was not the
primary factor in the development of a tuberculosis-specific gene
expression signature [71]. Rather, it is changes in cellular
composition and altered gene expression that drive such signa-
tures. The data presented here also indicates that the S. aureus
classifiers are not being driven by lineage-specific transcript
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abundance. Specifically, the total leukocyte count and cell lineage
distribution (based on routine automated differential measure-
ments) were not different between patients with S. aureus infection
and E. coli infection (15.76109/L with 86.2% neutrophils vs.
14.16109/L with 85.8% neutrophils, respectively). However, the
human S. aureus classifier was still able to differentiate infection due
to the two pathogens. The murine S. aureus classifier was highly
successful in differentiating S. aureus infection from healthy and
from E. coli infection yet was unable to differentiate E. coli from
healthy. This result would not be expected if transcript abundance
was driving the derivation of the classifier.
The overlap we observed in the gene expression response to S.
aureus infection in mouse and human was also consistent with
published studies. NF-kB signaling pathways have been identified
as a critical component of the murine response to infection [72],
which was mirrored in the murine and human data presented
here. Similar gene expression-based analyses of the human
response to bacterial infection have also revealed the importance
of other biological pathways including MHC class I and II antigen
presentation, immunological synapse formation, TGF-b receptor
signaling, TGF and WNT-dependent cytoskeleton remodeling,
and T-cell receptor signaling [10,18,73], all of which were
significantly associated with S. aureus infection in this study. Hence,
mice and humans utilize many of the same or overlapping
pathways in response to bacterial sepsis supporting the potential
utility of murine-based diagnostics for human disease.
S. aureus continues to evolve as a pathogen and leads to a
disproportionate burden of sepsis morbidity and mortality. This
study takes significant steps forward on multiple levels in the
ongoing effort to understand this pathogen; the host response to it;
and identify new diagnostic and therapeutic avenues. We describe
a potential diagnostic modality capable of differentiating infection
from health across species. More importantly, host gene expression
classifiers can differentiate infection due to S. aureus from that of E.
coli but this effect is less pronounced in the complex human host.
The approach described here also affords great insight into the
conserved and disparate pathways utilized by mice and humans in
response to these infections. Not only have we provided evidence
to support the paradigm shift in how we think about diagnostics,
but we have also identified new areas for research into the
pathways that subserve sepsis pathophysiology.
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pathogen.
(DOC)
Table S1 Probes, ranked by p-value, that were differ-
entially expressed (after Bonferroni correction) in mice
with S. aureus infection vs. Healthy controls; S. aureus
vs. E. coli infection; and E. coli vs. Healthy controls. Also
presented is the average probe expression in each comparator
group and the fold-change within the pairwise comparison.
(XLSX)
Table S2 Probes and corresponding genes that were
differentially expressed (after Bonferroni correction) in
mice with MRSA vs. MSSA infection.
(DOC)
Table S3 Probes, ranked by p-value, that were differ-
entially expressed (after Bonferroni correction) in
humans with S. aureus infection vs. Healthy controls;
S. aureus vs. E. coli infection; and E. coli vs. Healthy
controls. Also presented is the average probe expression in each
comparator group and the fold-change within the pairwise
comparison.
(XLSX)
Table S4 Pathway analysis for the genes from pairwise
comparisons in the mouse and human study. Top 50
ranked pathways from GeneGo MetaCore pathway analysis based
upon p-value. Shaded text corresponds to pathways that are
present in both the mouse and human response to the specified
pathogen.
(XLSX)
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Table S5 Genes in pathways common to murine and
human responses to infection. Human genes are in the
shaded cells. Murine genes are in the unshaded cells.
(XLSX)




Conceived and designed the experiments: SHA ELT DC CBC EPR SFK
JL CWW GSG VGF. Performed the experiments: SHA YZ. Analyzed the
data: SHA ELT DC JCVV RJL SWG JL VGF. Contributed reagents/
materials/analysis tools: CBC AKZ EPR RMO TV SFK JL CWW GSG
VGF. Wrote the paper: SHA ELT.
References
1. Klein E, Smith DL, Laxminarayan R (2007) Hospitalizations and deaths caused
by methicillin-resistant Staphylococcus aureus, United States, 1999–2005.
Emerg Infect Dis 13: 1840–1846.
2. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis
in the United States from 1979 through 2000. N Engl J Med 348: 1546–1554.
3. Lee A, Mirrett S, Reller LB, Weinstein MP (2007) Detection of bloodstream
infections in adults: how many blood cultures are needed? J Clin Microbiol 45:
3546–3548.
4. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial
treatment of infections: a risk factor for hospital mortality among critically ill
patients. Chest 115: 462–474.
5. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, et al. (2009) Initiation of
inappropriate antimicrobial therapy results in a fivefold reduction of survival in
human septic shock. Chest 136: 1237–1248.
6. Kim JH, Gallis HA (1989) Observations on spiraling empiricism: its causes,
allure, and perils, with particular reference to antibiotic therapy. Am J Med 87:
201–206.
7. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad
bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of
America. Clin Infect Dis 48: 1–12.
8. Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, et al. (2003)
Molecular characterization of the acute inflammatory response to infections with
gram-negative versus gram-positive bacteria. Infect Immun 71: 5803–5813.
9. Yu SL, Chen HW, Yang PC, Peck K, Tsai MH, et al. (2004) Differential gene
expression in gram-negative and gram-positive sepsis. Am J Respir Crit Care
Med 169: 1135–1143.
10. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, et al. (2007) Gene
expression patterns in blood leukocytes discriminate patients with acute
infections. Blood 109: 2066–2077.
11. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, et al. (1999) Differential
roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive
bacterial cell wall components. Immunity 11: 443–451.
12. Dziarski R, Wang Q, Miyake K, Kirschning CJ, Gupta D (2001) MD-2 enables
Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and
enhances TLR2-mediated responses to Gram-positive and Gram-negative
bacteria and their cell wall components. J Immunol 166: 1938–1944.
13. Cross ML, Ganner A, Teilab D, Fray LM (2004) Patterns of cytokine induction
by gram-positive and gram-negative probiotic bacteria. FEMS Immunol Med
Microbiol 42: 173–180.
14. Hessle CC, Andersson B, Wold AE (2005) Gram-positive and Gram-negative
bacteria elicit different patterns of pro-inflammatory cytokines in human
monocytes. Cytokine 30: 311–318.
15. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO 3rd, et al. (2009) Gene
expression signatures diagnose influenza and other symptomatic respiratory viral
infections in humans. Cell Host Microbe 6: 207–217.
16. Kawada J, Kimura H, Kamachi Y, Nishikawa K, Taniguchi M, et al. (2006)
Analysis of gene-expression profiles by oligonucleotide microarray in children
with influenza. J Gen Virol 87: 1677–1683.
17. Ng HH, Frantz CE, Rausch L, Fairchild DC, Shimon J, et al. (2005) Gene
expression profiling of mouse host response to Listeria monocytogenes infection.
Genomics 86: 657–667.
18. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, et al. (2009)
Enhanced monocyte response and decreased central memory T cells in children
with invasive Staphylococcus aureus infections. PLoS One 4: e5446.
19. Zaas AK, Aziz H, Lucas J, Perfect JR, Ginsburg GS (2010) Blood gene
expression signatures predict invasive candidiasis. Sci Transl Med 2: 21ra17.
20. Kim HS, Choi EH, Khan J, Roilides E, Francesconi A, et al. (2005) Expression
of genes encoding innate host defense molecules in normal human monocytes in
response to Candida albicans. Infect Immun 73: 3714–3724.
21. McDunn JE, Husain KD, Polpitiya AD, Burykin A, Ruan J, et al. (2008)
Plasticity of the systemic inflammatory response to acute infection during critical
illness: development of the riboleukogram. PLoS One 3: e1564.
22. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. (2008) A modular
analysis framework for blood genomics studies: application to systemic lupus
erythematosus. Immunity 29: 150–164.
23. Timofeeva AV, Goriunova LE, Khaspekov GL, Il’inskaia OP, Sirotkin VN, et
al. (2009) [Comparative transcriptome analysis of human aorta atherosclerotic
lesions and peripheral blood leukocytes from essential hypertension patients].
Kardiologiia 49: 27–38.
24. Dressman HK, Muramoto GG, Chao NJ, Meadows S, Marshall D, et al. (2007)
Gene expression signatures that predict radiation exposure in mice and humans.
PLoS Med 4: e106.
25. Rice KC, Firek BA, Nelson JB, Yang SJ, Patton TG, et al. (2003) The
Staphylococcus aureus cidAB operon: evaluation of its role in regulation of
murein hydrolase activity and penicillin tolerance. J Bacteriol 185: 2635–2643.
26. Miller RL, Ramsey GA, Krenitsky TA, Elion GB (1972) Guanine phosphor-
ibosyltransferase from Escherichia coli, specificity and properties. Biochemistry
11: 4723–4731.
27. Glickman SW, Cairns CB, Otero RM, Woods CW, Tsalik EL, et al. (2010)
Disease progression in hemodynamically stable patients presenting to the
emergency department with sepsis. Acad Emerg Med 17: 383–390.
28. Tsalik EL, Jones D, Nicholson B, Waring L, Liesenfeld O, et al. (2010) Multiplex
PCR to diagnose bloodstream infections in patients admitted from the
emergency department with sepsis. J Clin Microbiol 48: 26–33.
29. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions
for sepsis and organ failure and guidelines for the use of innovative therapies in
sepsis. The ACCP/SCCM Consensus Conference Committee. American
College of Chest Physicians/Society of Critical Care Medicine. Chest 101:
1644–1655.
30. Voora D, Ortel TL, Lucas JE, Chi JT, Becker RC, et al. (2010) Abstract 16293:
A Whole Blood RNA Signature Accurately Classifies Multiple Measures of
Platelet Function on Aspirin in Healthy Volunteers and Highlights a Common
Underlying Pathway. Circulation 122: A16293.
31. Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang QL, et al. (2008) High-
Dimensional Sparse Factor Modeling: Applications in Gene Expression
Genomics. Journal of the American Statistical Association 103: 1438–1456.
32. Wang Q, Carvalho C, Lucas JE, West M (2007) BFRM: Bayesian factor
regression modeling. Bulletin of the International Society of Bayesian Analysis
14: 4–5.
33. Hans C, Dobra A, West M (2007) Shotgun Stochastic search for ‘‘Large p’’
regression. Journal of the American Statistical Association 102: 507–516.
34. Raftery AE, Madigan D, Hoeting JA (1997) Bayesian model averaging for linear
regression models. Journal of the American Statistical Association 92: 179–191.
35. Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, et al. (2009) A genomic
strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell
34: 104–114.
36. Chen M, Carlson D, Zaas A, Woods CW, Ginsburg GS, et al. (2011) Detection
of viruses via statistical gene expression analysis. IEEE Trans Biomed Eng 58:
468–479.
37. Chen M, Zaas A, Woods CW, Ginsburg GS, Lucas JE, et al. (2011) Predicting
Viral Infection from High-Dimensional Biomarker Trajectories. Journal of the
American Statistical Association In Press.
38. Cyr DD, Lucas JE, Thompson JW, Patel K, Clark PJ, et al. (2011)
Characterization of serum proteins associated with IL28B genotype among
patients with chronic hepatitis C. PLoS One 6: e21854.
39. Lucas J, Carvalho C, West M (2009) A bayesian analysis strategy for cross-study
translation of gene expression biomarkers. Stat Appl Genet Mol Biol 8: Article
11.
40. Lucas JE, Kung HN, Chi JT (2010) Latent factor analysis to discover pathway-
associated putative segmental aneuploidies in human cancers. PLoS Comput
Biol 6: e1000920.
41. Meadows SK, Dressman HK, Daher P, Himburg H, Russell JL, et al. (2010)
Diagnosis of partial body radiation exposure in mice using peripheral blood gene
expression profiles. PLoS One 5: e11535.
42. Merl D, Lucas JE, Nevins JR, Shen H, West M (2009) Trans-study Projection of
Genomic Biomarkers in Analysis of Oncogene Deregulation and Breast Cancer.
In: O’Hagan T, West M, editors. The Oxford Handbook of Applied Bayesian
Analysis.
43. Ahn SH, Deshmukh H, Johnson N, Cowell LG, Rude TH, et al. (2010) Two
genes on A/J chromosome 18 are associated with susceptibility to Staphylococ-
cus aureus infection by combined microarray and QTL analyses. PLoS Pathog
6: e1001088.
44. von Kockritz-Blickwede M, Rohde M, Oehmcke S, Miller LS, Cheung AL, et al.
(2008) Immunological mechanisms underlying the genetic predisposition to
severe Staphylococcus aureus infection in the mouse model. Am J Pathol 173:
1657–1668.
45. Downey T (2006) Analysis of a multifactor microarray study using Partek
genomics solution. Methods Enzymol 411: 256–270.
Gene Expression Classifier for S. aureus Infection
PLOS ONE | www.plosone.org 15 January 2013 | Volume 8 | Issue 1 | e48979
46. Thakker M, Park JS, Carey V, Lee JC (1998) Staphylococcus aureus serotype 5
capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a
murine bacteremia model. Infect Immun 66: 5183–5189.
47. Xu W-f, Andersen H, Whitmore TE, Presnell SR, Yee DP, et al. (1998) Cloning
and characterization of human protease-activated receptor 4. Proceedings of the
National Academy of Sciences 95: 6642–6646.
48. Mueller A, O’Rourke J, Grimm J, Guillemin K, Dixon MF, et al. (2003) Distinct
gene expression profiles characterize the histopathological stages of disease in
Helicobacter-induced mucosa-associated lymphoid tissue lymphoma. Proc Natl
Acad Sci U S A 100: 1292–1297.
49. Zhang H, Su YA, Hu P, Yang J, Zheng B, et al. (2006) Signature patterns
revealed by microarray analyses of mice infected with influenza virus A and
Streptococcus pneumoniae. Microbes Infect 8: 2172–2185.
50. Desai KV, Kavanaugh CJ, Calvo A, Green JE (2002) Chipping away at breast
cancer: insights from microarray studies of human and mouse mammary cancer.
Endocr Relat Cancer 9: 207–220.
51. Larsson O, Scheele C, Liang Z, Moll J, Karlsson C, et al. (2004) Kinetics of
senescence-associated changes of gene expression in an epithelial, temperature-
sensitive SV40 large T antigen model. Cancer Res 64: 482–489.
52. Weindruch R, Kayo T, Lee CK, Prolla TA (2001) Microarray profiling of gene
expression in aging and its alteration by caloric restriction in mice. J Nutr 131:
918S–923S.
53. Wennmalm K, Wahlestedt C, Larsson O (2005) The expression signature of
in vitro senescence resembles mouse but not human aging. Genome Biol 6:
R109.
54. Lytkin NI, McVoy L, Weitkamp JH, Aliferis CF, Statnikov A (2011) Expanding
the understanding of biases in development of clinical-grade molecular
signatures: a case study in acute respiratory viral infections. PLoS One 6:
e20662.
55. Nau GJ, Schlesinger A, Richmond JF, Young RA (2003) Cumulative Toll-like
receptor activation in human macrophages treated with whole bacteria.
J Immunol 170: 5203–5209.
56. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, et al. (2002) Stereotyped
and specific gene expression programs in human innate immune responses to
bacteria. Proc Natl Acad Sci U S A 99: 972–977.
57. Tang BM, McLean AS, Dawes IW, Huang SJ, Cowley MJ, et al. (2008) Gene-
expression profiling of gram-positive and gram-negative sepsis in critically ill
patients. Crit Care Med. 1125–1128.
58. Sriskandan S, Cohen J (1999) Gram-positive sepsis. Mechanisms and differences
from gram-negative sepsis. Infect Dis Clin North Am 13: 397–412.
59. He M, Mangiameli DP, Kachala S, Hunter K, Gillespie J, et al. (2010)
Expression signature developed from a complex series of mouse models
accurately predicts human breast cancer survival. Clin Cancer Res 16: 249–259.
60. Labreche HG, Nevins JR, Huang E (2011) Integrating factor analysis and a
transgenic mouse model to reveal a peripheral blood predictor of breast tumors.
BMC Med Genomics 4: 61.
61. Deitch EA (1998) Animal models of sepsis and shock: a review and lessons
learned. Shock 9: 1–11.
62. Dyson A, Singer M (2009) Animal models of sepsis: why does preclinical efficacy
fail to translate to the clinical setting? Crit Care Med 37: S30–37.
63. Esmon CT (2004) Why do animal models (sometimes) fail to mimic human
sepsis? Crit Care Med 32: S219–222.
64. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS (2009)
Sepsis-induced human lymphocyte apoptosis and cytokine production in
‘‘humanized’’ mice. J Leukoc Biol 86: 219–227.
65. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat
sepsis and septic shock: a reassessment. Crit Care Med 25: 1095–1100.
66. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, et al. (1993)
Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in
lethal endotoxemia and function simultaneously as both TNF carriers and TNF
antagonists. J Immunol 151: 1548–1561.
67. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, et al. (1996) Treatment
of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The
Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697–1702.
68. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse
and human immunology. J Immunol 172: 2731–2738.
69. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, et al. (2008) Pyogenic
bacterial infections in humans with MyD88 deficiency. Science 321: 691–696.
70. Shanley TP, Cvijanovich N, Lin R, Allen GL, Thomas NJ, et al. (2007)
Genome-level longitudinal expression of signaling pathways and gene networks
in pediatric septic shock. Mol Med 13: 495–508.
71. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, et al. (2010) An
interferon-inducible neutrophil-driven blood transcriptional signature in human
tuberculosis. Nature 466: 973–977.
72. Chin CY, Monack DM, Nathan S (2010) Genome wide transcriptome profiling
of a murine acute melioidosis model reveals new insights into how Burkholderia
pseudomallei overcomes host innate immunity. BMC Genomics 11: 672.
73. Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, et al. (2009)
Genomic transcriptional profiling identifies a candidate blood biomarker
signature for the diagnosis of septicemic melioidosis. Genome Biol 10: R127.
Gene Expression Classifier for S. aureus Infection
PLOS ONE | www.plosone.org 16 January 2013 | Volume 8 | Issue 1 | e48979
